Influence of Chemotherapy on Gamma-delta T Cells in Patients With Epithelial Ovarian Cancer (IClyCO)
|ClinicalTrials.gov Identifier: NCT01606358|
Recruitment Status : Withdrawn
First Posted : May 25, 2012
Last Update Posted : August 11, 2014
In patients with an ovarian cancer, the treatment is currently based on surgery and chemotherapy.
The impact of chemotherapy on the expansion and functional abilities of Vgamma9Vdelta2 T cells has never been evaluated.
The long term goal is to give a rational to combine conventional treatment of ovarian cancer with immunotherapy based on Vgamma9Vdelta2 T cells.
|Condition or disease||Intervention/treatment|
|Ovarian Cancer||Drug: Carboplatin and / or taxol chemotherapy|
Ovarian cancer is associated with a high mortality rate. Treatment of ovarian cancer is currently based on surgery and chemotherapy.
The first surgery is a radical surgical procedure aiming to achieve no residual disease. Patients who could not benefit from the first surgery may be offered neoadjuvant chemotherapy with a new surgical procedure after 3 or 6 chemotherapy cycles. Chemotherapy is currently based on Taxol and Carboplatin. Immunotherapy based on Vgamma9Vdelta2 T cells could provide a promising therapeutic strategy, however, the impact of chemotherapy on the expansion and functional abilities of Vgamma9Vdelta2 T cells has never been evaluated.
We want to study the effect of chemotherapy of ovarian cancer on Vgamma9Vdelta2 T cells rates in the peripheral blood of patients with ovarian cancer.
Functional abilities of the Vgamma9Vdelta2 T cells will be studied: expansion after chemotherapy and their cytotoxic abilities in an autologous context before or after chemotherapy.
The long term goal is to give a rational to combine conventional treatment of ovarian cancer with non-conventional treatment such as immunotherapy based on Vgamma9Vdelta2 T cells.
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||IClyCO Influence of Chemotherapy (Carboplatin and Taxol) on the ex Vivo Expansion and Functional Capacity of Gamma-delta T Cells in Patients With Epithelial Ovarian Cancer|
|Estimated Primary Completion Date :||May 2016|
U.S. FDA Resources
Drug: Carboplatin and / or taxol chemotherapy
Patient with proven epithelial ovarian cancer and receiving carboplatin and / or taxol chemotherapy (usual care).
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01606358
|CHU de RENNES|
|Rennes, France, 35000|
|Study Chair:||Bruno Laviolle, MD PhD||Rennes University Hospital|